Patrick Campbell

Outlook Therapeutics announced receipt of the CRL exactly one year after resubmission of their BLA for ONS-5010 as a treatment for wet age-related macular degeneration, which would have been the first indication for a retinal disease given to an ophthalmic version of bevacizumab.

A prespecified analysis of the CLEAR Outcomes trial assessing outcomes according to glycemic status suggests bempedoic acid provided similar relative benefits across the glycemic spectrum, but the greatest absolute benefits were observed in patients with diabetes.

A trio of studies and new guidelines presented at the ESC Congress 2023 highlight advancement in the management of hypertrophic cardiomyopathy, particularly with use of mavacamten.

On August 29, 2023, the Biden Administration debuted the list of the first 10 drugs identified for price negotiation under the Inflation Reduction Act. The list, which includes agents indicated for diabetes, heart failure, GI conditions, and arthritis, accounted for more than $50 billion in spending during the evaluation period.

Results of the 56-week VALOR-HCM trial provide new insight into the effects of mavacamten in patients with highly symptomatic obstructive hypertrophic cardiomyopathy referred for septal reduction therapy.

Results of the FRAIL-AF trial at ESC Congress 2023 provide clinicians with further clarity into the effects of switching from vitamin K antagonists to NOACs in older patients with frailty and atrial fibrillation.

With BridgeBio Pharma Inc. expecting to complete a regulatory submission prior to the close of 2023, the 30-month results of ATTRibute-CM provide the most comprehensive overview yet of the benefit-risk profile for acoramidis in ATTR-CM.

Javed Butler, MD, discusses the overall results of the STEP-HFpEF trial, how he interprets the reduction in adjudicated heart failure events, and how the community's recent experience with SGLT2 inhibitors might inform uptake strategies for semaglutide 2.4 mg.

The largest trial to date, a meta-analysis, and new guideline recommendations have placed a spotlight on the role and benefit of iron supplementation in patients with heart failure and iron deficiency at ESC Congress 2023.

Citing more than half a dozen major trials in the 2 years since the release of their 2021 heart failure guidelines, the European Society of Cardiology has released a focused update to their heart failure guidance.

Results of the STEP-HFpEF trial suggest use of semaglutide 2.4 mg (Wegovy) was associated with improvements in physical symptoms and functional status relative to placebo therapy in adults with HFpEF and obesity.

An analysis of data from more than 30,000 people with type 2 diabetes provides insight into the long-term use of metformin and risk of vitamin B12 deficiency.

A pair of experts in the management of hypertrophic cardiomyopathy provide insight into the recent advances in management and reflect on what these advances have meant for patients.

An analysis of data from CREDENCE provides insight into the prognostic potential of a group of 4 common biomarkers for predicting cardiovascular and kidney issues in people with type 2 diabetes.

Using data and eligibility criteria from the STEP 1 trial, a California-based team estimates 93 million US adults met criteria for semaglutide 2.4 mg and use could prevent 1.5 million incident cardiovascular events over a 10-year period.

An analysis of data from a NYC-based health system indicate more than 1 in 5 people hospitalized for COVID-19 and 1 in 10 nonhospitalized COVID-19 patients went on to develop persistent hypertension 6 months later.

With approval, aflibercept 8 mg becomes the first and only treatment approved in wet AMD and DME for immediate dosing at 8-week and up to 16-week intervals following 3 initial monthly doses.

The FDA approval of pozelimab (Veopoz) makes it the first and only treatment indicated for children and adults with CHAPLE disease.

A study led by Massachusetts General Hospital is offering insight into the antibody response achieved with each dose of mRNA vaccines among heart and lung transplant recipients relative to their healthy counterparts.

A posthoc analysis of the pivotal SOLOIST-WHF trial provides insight into the effects of sotagliflozin use on risk of cardiovascular mortality and heart failure readmissions at 90 days.

In a Q&A, Clipper Young, PharmD, MPH, discusses the Pharm2Home Initiative based on his presentation from ADCES 2023 and describes the impact of community-driven, pharmacist-led interventions to improve health literacy in those with chronic disease.

Michael J. Blaha, MD, MPH, discusses his interpretation of the growing data detailing the role of inflammation as a driver of cardiovascular risk and how clinicians can identify patients who stand to benefit most from colchicine 0.5 mg tablets.

Joshua Neumiller, PharmD, takes part in a Q&A on the role of deprescribing in older adults with diabetes mellitus based on a presentation from the Association of Diabetes Care and Education Specialists 2023 annual meeting.

In a recent Q&A, Michael Blaha, MD, discusses how he views the ideal role of cardiologists in the management of obesity and how this role could change based on the results of the SELECT trial.

At ADCES 2023, Halis Akturk, MD, presented data calling attention to the risk of hyperglycemic ketosis-cannabis hyperemesis syndrome in people with type 1 diabetes.

Novo Nordisk has announced topline data from the SELECT trial, which suggest use of once-weekly semaglutide 2.4 mg was associated with a statistically significant 20% reduction in 3-point MACE among a cohort with overweight or obesity and established cardiovascular disease.

An analysis of real-world data provides an overview of the effects of GLP-1 receptor agonist and SGLT2 inhibitor use among adults with type 1 diabetes.

The July 2023 cardiology month in review features a Class I recall from the FDA, the latest recommendation statement from the USPSTF, and an update on 3 agents in the pipeline.

An analysis of data from more than 80,000 patients using statins suggests the initial benefit on LDL-C reduction was greater for older patients than younger patients.

Our July 2023 endocrinology month in review features an FDA approval, topline results from a pair of major trials, and a pair of new guidelines related to the management and diagnosis of diabetes.